Placeholder Banner

BIO comments to the United States Patent and Trademark Office’s (USPTO) RE: Artificial Intelligence and Inventorship

May 15, 2023

BIO’s submission is in response to the USPTO’s Request for Comments (88 FR 9492, February 14, 2023)

Download Full Comments Below
BIO comments to the United States Patent and Trademark Office’s (USPTO) RE: Artificial Intelligence and Inventorship

BIO’s submission is in response to the USPTO’s Request for Comments (88 FR 9492, February 14, 2023)

Discover More
In these comments, BIO addresses FDA’s four specific topic areas of consideration as the agency develops its draft guidance per PDUFA VII.
BIO joined with more than 40 groups in calling on Congress to set 2024 funding for the U.S. Codex Office at or above the 2023 level. 
BIO’s comments support accelerated approval as an important regulatory pathway that allows patients with serious and life-threatening illnesses such as cancer to have earlier access to promising therapies.